» Articles » PMID: 19965633

Integrated Biochemical and Computational Approach Identifies BCL6 Direct Target Genes Controlling Multiple Pathways in Normal Germinal Center B Cells

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2009 Dec 8
PMID 19965633
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

BCL6 is a transcriptional repressor required for mature B-cell germinal center (GC) formation and implicated in lymphomagenesis. BCL6's physiologic function is only partially known because the complete set of its targets in GC B cells has not been identified. To address this issue, we used an integrated biochemical-computational-functional approach to identify BCL6 direct targets in normal GC B cells. This approach includes (1) identification of BCL6-bound promoters by genome-wide chromatin immunoprecipitation, (2) inference of transcriptional relationships by the use of a regulatory network reverse engineering approach (ARACNe), and (3) validation of physiologic relevance of the candidate targets down-regulated in GC B cells. Our approach demonstrated that a large set of promoters (> 4000) is physically bound by BCL6 but that only a fraction of them is repressed in GC B cells. This set of 1207 targets identifies several cellular functions directly controlled by BCL6 during GC development, including activation, survival, DNA-damage response, cell cycle arrest, cytokine signaling, Toll-like receptor signaling, and differentiation. These results define a broad role of BCL6 in preventing centroblasts from responding to signals leading to exit from the GC before they complete the phase of proliferative expansion and of antibody affinity maturation.

Citing Articles

Identification of B Cell Subpopulations with Pro- and Anti-Tumorigenic Properties in an Immunocompetent Mouse Model of Head and Neck Squamous Cell Carcinoma.

Sonntag M, Stanojevic S, Laban S, Schuler P, Hoffmann T, Brunner C Cells. 2025; 14(1.

PMID: 39791721 PMC: 11720715. DOI: 10.3390/cells14010020.


Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment.

Guan X, Wang Y, Fang T, Wang J, Li R, Hao M Haematologica. 2024; 110(2):425-438.

PMID: 39323416 PMC: 11788625. DOI: 10.3324/haematol.2024.285304.


Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia.

Xiao Y, Deng F, Luo Y, Wang T Heliyon. 2024; 10(16):e36640.

PMID: 39258188 PMC: 11386027. DOI: 10.1016/j.heliyon.2024.e36640.


The F-box E3 ligase protein FBXO11 regulates EBNA3C-associated degradation of BCL6.

Sun K, Bose D, Singh R, Pei Y, Robertson E J Virol. 2024; 98(7):e0054824.

PMID: 38864622 PMC: 11265398. DOI: 10.1128/jvi.00548-24.


Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy.

Worley J, Noh H, You D, Turunen M, Ding H, Paull E bioRxiv. 2024; .

PMID: 38798673 PMC: 11118419. DOI: 10.1101/2023.11.08.562798.


References
1.
Dhordain P, Lin R, Quief S, Lantoine D, Kerckaert J, Evans R . The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998; 26(20):4645-51. PMC: 147883. DOI: 10.1093/nar/26.20.4645. View

2.
Smith A, Sumazin P, Zhang M . Identifying tissue-selective transcription factor binding sites in vertebrate promoters. Proc Natl Acad Sci U S A. 2005; 102(5):1560-5. PMC: 547828. DOI: 10.1073/pnas.0406123102. View

3.
Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

4.
Song L, Alimirah F, Panchanathan R, Xin H, Choubey D . Expression of an IFN-inducible cellular senescence gene, IFI16, is up-regulated by p53. Mol Cancer Res. 2008; 6(11):1732-41. DOI: 10.1158/1541-7786.MCR-08-0208. View

5.
Cattoretti G, Chang C, Cechova K, Zhang J, Ye B, Falini B . BCL-6 protein is expressed in germinal-center B cells. Blood. 1995; 86(1):45-53. View